newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//News-Medical.net
The 2026 EANM Young Scientist Network Award aims to accelerate innovative research in alpha radioligand therapy (α-RLT) in prostate cancer.
Applications are open for the inaugural 2026 EANM Young Scientist Network Award targeting α-RLT research.
KEY POINTS
The award focuses specifically on alpha radioligand therapy in prostate cancer research.
Winners will receive Platinum (€40,000), Gold (€20,000), or Silver (€10,000) awards.
Eligibility is limited to researchers within 10 years of their terminal degree in EANM member countries.
Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), aims to accelerate innovative research in alpha radioligand therapy (α-RLT) in prostate cancer. Winners will be recognized across three award categories: Platinum (40,000 euros), Gold (20,000 euros), and Silver (10,000 euros) awards.
Alpha radioligand therapy is rapidly emerging as a transformative frontier in precision oncology, and we strongly believe in the talent of researchers at the beginning of their careers in this field. This award was designed to nurture their growth by pairing research excellence with structured training, mentorship, and collaborative networking opportunities."
Paola Anna Erba, EANM President
Shaping the future of prostate cancer
EANM invites applications from early career researchers - PhD candidates, postdoctoral fellows, junior faculty, and clinicians-in-training - who are within 10 years of their terminal degree and affiliated with an institution in an EANM member country.